🟢 GILD is trading 3.5% up today as HSBC dismisses HIV generic competition fears

GILD is trading 3.5% up at $134.19 following a bullish upgrade from HSBC regarding the company's HIV franchise.

• HSBC raised its rating on Gilead to Buy from Hold and increased its price target to $155.
• Analysts argue the market is overly pessimistic about generic competition, highlighting long-acting therapies as a primary driver for adherence and long-term growth.